giovedì, 23 marzo 2023
15 Dicembre 2017

FDA Grants Priority Review to Pembrolizumab for Relapsed/Refractory PMBCL

December 11, 2017 – The FDA has granted a priority review to a supplemental biologics license application (sBLA) for pembrolizumab as a treatment for adult and pediatric patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL). Merck, the manufacturer of pembrolizumab, issued a press release announcing the agency’s decision on December 11, 2017. The findings were first presented at the 14th International Conference on … (leggi tutto)